Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A new analysis of data show that Roche and Trimeris' co-developed HIV fusion inhibitor Fuzeon continued to provide immune system benefits in some patients even though their virus was resistant to the drug and continued to replicate
Subscribe to our email newsletter
The new data were presented at the 15th International HIV Drug Resistance Workshop in Sitges, Spain.
The correlation of certain Fuzeon resistance mutations with the observed increases in CD4 immune cells, corroborate the findings of other investigators presented in earlier this year.
Fuzeon is the first and only HIV fusion inhibitor. Unlike other HIV drugs that work after HIV has entered the human immune cell, Fuzeon works by blocking the virus from entering the human immune cell.
“This new analysis from the TORO studies confirms a similar analysis from our research and shows that Fuzeon-related resistance mutations may be associated with maintenance of CD4 cell counts or even continued CD4 improvements in some patients,” said Dr Carlo Federico Perno, professor of virology at the University of Rome Tor Vergata, Italy.